Loss of skeletal muscle mass during palliative chemotherapy is a poor prognostic factor in patients with advanced gastric cancer
Abstract Cancer causes muscle mass loss, which is associated with a poor prognosis. Chemotherapy may also reduce muscle mass. We investigated skeletal muscle mass change during palliative chemotherapy for advanced gastric cancer (AGC) and its association with treatment outcomes. We retrospectively r...
Main Authors: | Song Ee Park, Jin Hwa Choi, Jae Yong Park, Beom Jin Kim, Jae Gyu Kim, Jong Won Kim, Joong-Min Park, Kyong-Choun Chi, In Gyu Hwang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2020-10-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-020-74765-8 |
Similar Items
-
Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case
by: Park Joong-Min, et al.
Published: (2010-12-01) -
Gastric Gastrointestinal Stromal Tumor with Repeated Recurrence at the Anastomosis Site in a Very Elderly Patient
by: Hye-Jin Kim, et al.
Published: (2020-10-01) -
Atypical Scar Patterns after Gastric Endoscopic Submucosal Dissection
by: Bomin Kim, et al.
Published: (2021-03-01) -
Combination versus single-agent as palliative chemotherapy for gastric cancer
by: Jin-Hyuk Choi, et al.
Published: (2020-03-01) -
Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer
by: Hwang Jun-Eul, et al.
Published: (2011-11-01)